AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05896228
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive Carfilzomib (K) therapy intravenously (IV) as follows:~* Cycle 1: 20 mg/m2 per dose on Day 1; 56 mg/m2 per dose on Days 8 and 15~* Cycles 2 to 8: 56 mg/m2 per dose on Days 1, 8, and 15.
Trial: NCT05896228
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive Daratumumab (D) therapy subcutaneously (SC) or intravenously (IV) as follows:~* Cycles 1 and 2: 1800 mg SC or 16 mg/kg IV on Days 1, 8, 15, and 22~* Cycles 3 through 6: 1800 mg SC or 16 mg/kg IV on Days 1 and 15~* Cycles 7 and 8: 1800 mg SC or 16 mg/kg IV on Day 1.
Trial: NCT04767217
Drug: dihydroartemisinin-piperaquine (DHA-PPQ)
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dihydroartemisinin-piperaquine (DHA-PPQ)
Trial: NCT05896228
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive Dexamethasone (d) therapy either orally (PO) or intravenously (IV) as follows:~* Cycles 1 and 2: 40 mg/dose on Days 1, 8, and 15; 20 mg/dose on Day 22~* Cycles 3 and 4: 40 mg/dose on Days 1, 8, and 15~* Cycles 5 through 8: 20 mg/dose on Days 1, 8, and 15.
Trial: NCT05896228
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive Diphenhydramine either orally (PO) or intravenously (IV) prior to Iber-KDd therapy as follows:~* Cycles 1 and 2: 25 mg/dose on Days 1, 8, 15, and 22~* Cycles 3 through 6: 25 mg/dose on Days 1 and 15~* Cycles 7 and 8: 25 mg/dose on Day 1.
Trial: NCT05896228
Drug: Montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive Montelukast orally (PO) prior to Iber-KDd as follows:~* Cycle 1 only: 10 mg/dose, Days 1, 8, 15, and 22, to be administered prior to the first 4 doses of Daratumumab (D).
Trial: NCT05060523
Drug: Tolvaptan Tablets
RxNorm normalized name: Tolvaptan Tablets
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: • Tolvaptan15 mg once a day for 7 days, stat with 7.5 mg and titrate to 15 mg in 24 hours max30 mg
Trial: NCT05060523
Drug: Midodrine Oral Tablet
RxNorm normalized name: midodrine Oral Tablet
DrugBank: Midodrine (DB00211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: • Midodrine 5 mg at 0 hours and then 5 mg every 8 hours to maintain Target MAP-80
Trial: NCT04973189
Drug: SHR-1707
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of SHR-1707 by intravenous (IV) infusion in healthy young adults.
Trial: NCT04973189
Drug: SHR-1707
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of SHR-1707 by intravenous (IV) infusion in elderly subjects.
Trial: NCT06801522
Drug: 0.1% xylometazoline nasal drops
DrugBank: Xylometazoline (DB06694)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xylometazoline is direct acting, non selective, adrenergic agonist binding with alpha 1\&2 receptors, used for vasoconstriction to decrease nasal bleeding.
Trial: NCT05474937
Drug: Sevoflurane Inhalation Solution
RxNorm normalized name: sevoflurane Inhalation Solution
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in inhalational group will receive Sevoflurane at 7% dial concentration in 100% O2 by an appropriately sized face mask until adequate sedation occurs as adequate jaw relaxation for the endoscope insertion and attainment of Modified Ramsay Sedation Score (MRSS) 7 (i.e., Asleep, reflex withdrawal to painful stimuli only).
Trial: NCT05474937
Drug: Midazolam, Ketamine and Propofol
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Preoxygenation with 100% O2 for 1 minute, by proper sized face mask. Patients in Ketamine -midazolam -propofol (KMP) group will receive 1-1.5 mg/kg IV ketamine and 0.05mg/kg IV Midazolam and 1mg/kg IV Propofol as induction dose then followed by incremental doses of 0.5 mg/kg IV Propofol alone for maintenance and if procedure is prolonged propofol infusion at 100 μg/kg/min is given for maintenance of sedation. Induction dose will be considered as adequate if adequate jaw relaxation for endoscope insertion and Modified Ramsay Sedation Score (MRSS) ≥7 occurs with maintenance of spontaneous respiration. Induction time will be considered as time from beginning of IV agent to achievement of MRSS ≥7. After endoscope insertion, maintenance of oxygenation by nasal cannula at flow twice the minute ventilation of the patient
Trial: NCT06802042
Drug: Lactulose oral solution treatment
RxNorm normalized name: lactulose Oral Solution
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The control group (n=20) received lactulose oral solution free of charge for 4 weeks (1-2 bags qd for the first three days, and then increased or reduced according to constipation)
Trial: NCT04817527
Drug: Edaravone Dexborneol
DrugBank: Borneol (DB11288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injections of edaravone dexborneol (37.5mg in 0·9% NaCl) BID for 7-14days.
Trial: NCT05597345
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Low-dose Selinexor for the Treatment of Intermediate to High-Risk Smoldering Multiple Myeloma
Trial: NCT06778811
Drug: Intraoperative infusion of dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraoperative infusion of 0.3ug/kg/h dexmedetomidine
Trial: NCT06778811
Drug: Intraoperative infusion of esketamine
RxNorm normalized name: esketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intraoperative infusion of 0.3mg/kg/h esketamine
Trial: NCT06778811
Drug: Saline control
RxNorm normalized name: GLYCERIN 0.53 g in 1 mL CUTANEOUS INJECTION [Glycerol-Saline Control]
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative infusion of equal volumes of saline
Trial: NCT06319521
Drug: Lidocaine hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Trial: NCT05661669
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention will consist of a single infusion of ketamine in the ED at a dose of 0.8mg/kg over 40 minutes.
Trial: NCT05661669
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The placebo will be a 0.9% saline solution administered over 40 minutes.
Trial: NCT05332366
Drug: Delgocitinib cream
RxNorm normalized name: Delgocitinib
DrugBank: Delgocitinib (DB16133)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Cream for topical application
Trial: NCT05332366
Drug: Delgocitinib cream vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Delgocitinib (DB16133)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
Trial: NCT06228079
Drug: Immunotherapy,Toripalimab Injection
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the experimental group would be implemented with adjuvant Immunotherapy and chemotherapy after endoscopic surgery. Four to six cycles chemotherapy and 10 cycles immunotherapy,or until unacceptable side effects.
Trial: NCT05660473
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-tumor alkaloids
Trial: NCT05660473
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Anthracycline
Trial: NCT05660473
Drug: Pegaspargase
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol (PEG) conjugated to L-asparaginase
Trial: NCT05660473
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucocorticoids
Trial: NCT05660473
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pyrimidine antimetabolites
Trial: NCT05660473
Drug: 6-mercaptopurine
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cell cycle-specific antitumor drug
Trial: NCT05660473
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glucocorticoids
Trial: NCT05660473
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Selective inhibitor of B-cell lymphoma 2 (Bcl-2)
Trial: NCT06793137
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This intervention involves administering the oral antibiotic metronidazole during the first seven days of radiotherapy for patients with locally advanced rectal adenocarcinoma who are undergoing total neoadjuvant treatment. Metronidazole is considered a safe medication, with a very low risk of adverse effects. It is commonly used to treat infections caused by anaerobic bacteria that are part of the intestinal microbiota. Additionally, it is well established that certain genera of anaerobic bacteria are linked to a poorer response to treatment.
Trial: NCT06280950
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * The first step is the addition of everolimus to participants in this group pre-randomization.~* Participants on a mycophenolate compound will stop taking it within 7 days of initiating everolimus, either by immediate discontinuation or a 7-day taper.~* Participants taking prednisone will taper off prednisone by 6 months post-transplant.~* The second step is tacrolimus minimization and withdrawal to everolimus monotherapy in this group after randomization.
Trial: NCT06280950
Drug: Tacrolimus (continued reduction)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Participants randomized in this cohort will have their tacrolimus dose reduced by 50% following randomization.~* They will maintain this daily dose for 4 weeks/1 month (28-30 days). Tacrolimus withdrawal will occur in intervals of 30 days or 4 weeks.~* Each subsequent reduction will be based on LFT stability over the prior time interval before the next reduction
Trial: NCT06280950
Drug: Tacrolimus (maintain 50% reduction)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: - Participants randomized in this cohort maintain initial reduced dose of Tacrolimus and everolimus for study duration.
Trial: NCT06280950
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * The first step is the addition of everolimus to participants in the interventional group pre-randomization.~* Participants on a mycophenolate compound will stop taking it within 7 days of initiating everolimus, either by immediate discontinuation or a 7-day taper.~* Participants taking prednisone will taper off prednisone by 6 months post-transplant.~* The second step is to continue on the reduced tacrolimus and everolimus regimen.
Trial: NCT05600179
Drug: Dexamethasone intravitreal implant
RxNorm normalized name: Dexamethasone Intravitreal Implant
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone intravitreal implant
Trial: NCT05203588
Drug: Denosumab 60 mg/ml Injectable Solution [Prolia]
RxNorm normalized name: denosumab 60 MG/ML Injectable Solution [Prolia]
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab, 60mg(1ml), subcutaneously, totally two times, with one time at 1-week postoperatively and another time at 26-week postoperatively.
Trial: NCT05993975
Drug: Dexmedetomidine Hydrochloride
RxNorm normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Use of Dexmedetomidine Hydrochloride 5 micrograms (1 mL) as an adjuvant with bupivacaine hydrochloride
Trial: NCT04840355
Drug: Sintilimab Injection
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The recommended dose for intravenous infusion is 200 mg on day 1.Courses repeat every 21 days for up to 6 months in the absence of disease progression or unacceptable toxicity.
Trial: NCT00005665
Drug: interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05050682
Drug: PF-07304814
RxNorm normalized name: PF-07304814
DrugBank: PF-07304814 (DB16514)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07304814 is an anti-viral, formulated for intravenous delivery
Trial: NCT05972551
Drug: Romosozumab
RxNorm normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous (SC) injection
Trial: NCT05972551
Drug: Bisphosphonate
RxNorm normalized name: Bisphosphonate
DrugBank: [{(5-Chloro-2-Pyridinyl)Amino} Methylene]-1,1-Bisphosphonate (DB03649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration determined by investigator according to the local standard of care
Trial: NCT05260957
Drug: Mosunetuzumab
RxNorm normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction Phase (Days -42 through -7):~* 1 mg of Mosunetuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Day -42.~* 2 mg of Mosunetuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Day -35.~* 60 mg of Mosunetuzumab administered via intravenous (IV) infusion on (given as per treatment guidelines) on Days -28 and -7.~Consolidation Phase (Day +1 through Day +90): 30 mg IV Mosunetuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Days +14, +35, +56 and +77.
Trial: NCT05260957
Drug: Polatuzumab
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction Phase (Days -42 through -7): 1.8mg/kg of Polatuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Day -28.~Consolidation Phase (Days +1 through +90): 1.8mg/kg of Polatuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Days +35, +56 and +77.
Trial: NCT05280873
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 2 mg / kg / d . Methylprednisolone was gradually reduced after the improvement of symptoms and imaging. The treatment course was 6-8 weeks
Trial: NCT06289192
Drug: Nicotine Replacement Product
RxNorm normalized name: nicotine Inhalant Product
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be offered a 12-week supply of nicotine patches and either nicotine gum or lozenges.
Trial: NCT05477576
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus
Trial: NCT05477576
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib
Trial: NCT05477576
Drug: Octreotide
RxNorm normalized name: Octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: High-dose octreotide
Trial: NCT05477576
Drug: Lanreotide
RxNorm normalized name: Lanreotide
DrugBank: Lanreotide (DB06791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lanreotide
Trial: NCT05088876
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol in the dose already used
Trial: NCT05199311
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg/m2 C1D1; 56 mg/m2 thereafter
Trial: NCT05199311
Drug: Iberdomide
RxNorm normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle
Trial: NCT05199311
Drug: Oral Dexamethasone
RxNorm normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg (\<=75 years old); 20 mg (\>75 years old)
Trial: NCT06469138
Drug: Bemcentinib
RxNorm normalized name: Bemcentinib
DrugBank: Bemcentinib (DB12411)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 200 mg dose contains approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib and is administered as a single dose on Day 1 of the study.
Trial: NCT05558124
Drug: Vyxeos
RxNorm normalized name: Vyxeos
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fixed dose of Vyxeos (44 mg/m2 daunorubicin and 100 mg/m2 cytarabine) (Day 1, 3, and 5) in combination with various dose schedules of Gemtuzumab Ozogamicin (GO)
Trial: NCT05558124
Drug: Gemtuzumab Ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will be treated at the following dose levels:~Dose Level 1 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1 Dose Level 2 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1 and 4 Dose Level 3 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1, 4, 7
Trial: NCT04718805
Drug: Darunavir
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive a single dose of Darunavir tablets orally as per assigned treatment sequence.
Trial: NCT04718805
Drug: Cobicistat
RxNorm normalized name: Cobicistat
DrugBank: Cobicistat (DB09065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participant will receive a single dose of Cobicistat tablets orally as per assigned treatment sequence.
Trial: NCT04718805
Drug: Darunavir/Cobicistat FDC
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive a single dose of darunavir and cobicistat FDC tablets orally as per assigned treatment sequence.
Trial: NCT05515406
Drug: ONO-7018
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO-7018 tablet(s) are administered orally
Trial: NCT06086418
Drug: 0.9 % Sodium Chloride
RxNorm normalized name: 0.9 % sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block
Trial: NCT06086418
Drug: 0.1mg/kg Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block
Trial: NCT06086418
Drug: 0.05mg/kg Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.05mg/kg Dexamethasone for the popliteal nerve block
Trial: NCT05230758
Drug: Metformin hydrochloride (HCl) 500mg tablet
RxNorm normalized name: metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin HCl 500mg tablets contain 500mg of active pharmaceutical ingredient (API) and are white, round, biconvex, film-coated tablets, with a score line on one face and debossed with HMR on the other. Each tablet contains the non-medicinal ingredients magnesium stearate and povidone. Tablet coating is comprised of hydroxypropyl methylcellulose, polyethylene glycol and titanium dioxide.
Trial: NCT04907747
Drug: Vonoprazan
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Potassium-competitive acid blocker
Trial: NCT04907747
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor
Trial: NCT04907747
Drug: Colloidal bismuth pectin
RxNorm normalized name: bismuth / pectin
DrugBank: Pectin (DB11158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric mucosal protective drug with anti-H. pylori effect
Trial: NCT04907747
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic for H. pylori eradication
Trial: NCT04907747
Drug: Furazolidone
RxNorm normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic for H. pylori eradication
Trial: NCT05588453
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO